Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA).
Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing.
This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities.
The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed.
Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.'
About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.
For additional information, see: https://advicenne.com/.
Disclaimer
This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
21 minutes ago
- USA Today
NBA sets schedule for 2025-26 games in Europe, unveils plans for 2027, 2028
The NBA on Wednesday announced its regular-season European schedule for the 2025-26 season and unveiled plans to play regular-season season games in Paris, Berlin and Manchester in 2027 and 2028. The Memphis Grizzlies and Orlando Magic will play two games in Europe this season – in Berlin on Jan. 15, and in London on Jan. 18. "Announcing the next three season's regular-season games in Europe reflects the incredible momentum and appetite for NBA basketball in France, Germany, the UK and across the region," NBA managing director of Europe and Middle East George Aivazoglou said in a news release. "We look forward to welcoming the Grizzlies and the Magic to Berlin and London and to engaging fans, players and the local communities through the games and the surrounding events." The Magic's Franz and Mo Wagner are from Germany, and the Berlin game will the NBA's first regular-season game in the country. "To have the Orlando Magic and the NBA play a regular-season game in our hometown of Berlin means everything to us," the Wagner brothers said in a joint statement. "Growing up here, we dreamed of moments like this. It's a huge honor to represent Berlin and Germany and show how much the city and country love basketball. We hope we can inspire kids the way we were inspired watching games from afar." Europe, get ready! ✈️🌍The NBA will host SIX regular-season games in Europe over the next three years, with games to come in Berlin and London (2026), Manchester and Paris (2027) and Berlin and Paris (2028).🗞️ The NBA's push into the European market has been steady and unsurprising. As the league considers expansion of its North American-based league, it is also exploring the creation a new league based in Europe – with the idea of adding already existing franchises and creating franchises in underserved markets. "Just as the same as in American cities, we think there's an opportunity to serve fans in Europe," NBA commissioner Adam Silver said at the NBA Finals. "No knock on European basketball, because most of those international MVPs I just talked about are coming from Europe. There's really high-level basketball being played there. But we think there is an opportunity to better serve fans there. I view that as a form of expansion as well, and that's something we're also thinking hard about."
Business Wire
21 minutes ago
- Business Wire
Vista Building at The Wellington at North Bend Crossing Secures Ohio Licensure, Opening Doors for New Assisted Living and Memory Care Residents
CINCINNATI--(BUSINESS WIRE)--Sonida Senior Living, Inc. (NYSE: SNDA), a national provider of senior housing, announced today that the newly constructed Vista building at The Wellington at North Bend Crossing has received its Ohio Residential Care Facility license from the Ohio Department of Health, completing the final step before welcoming Assisted Living and Memory Care residents. The approval follows a successful, deficiency-free survey on June 16, 2025, underscoring Sonida's commitment to quality, safety, and resident-centered care. 'Securing licensure is more than a regulatory milestone, it's our green light to serve families who have been eagerly awaiting Vista's opening,' said Kevin Potts, Executive Director at The Wellington at North Bend Crossing. 'With Sage and SafelyYou technology already in place, residents will move into an environment where safety, engagement, and dignity come first.' Community Highlights Resident-first technology: Integration of Sage OS (a next-gen nurse call operating system) and SafelyYou (AI fall-detection with rapid staff alerts), giving families greater peace of mind and helping care teams respond quickly and effectively. Job creation: Nearly 65 new positions across care, dining, and life-enrichment teams. Amenities: Three outdoor spaces, 1,000-sq-ft rehab gym, theater, multiple dining venues, salon, sunrooms on every floor, and more. Flexible stays: Fully furnished Assisted Living suites available for respite and short-term recovery. What Licensure Means for Families Licensure ensures that Vista meets or exceeds all state standards for staffing, life-safety, and clinical care. Combined with Sonida's Joyful Living™ philosophy and Magnolia Trails™ memory-care program, the approval allows residents to age in place, transitioning seamlessly from independent living to higher levels of support without leaving the campus they call home. 'Vista exemplifies our growth strategy: purposeful expansions that elevate the resident experience and strengthen local economies,' said Brandon Ribar, President & CEO of Sonida Senior Living. 'We're extremely proud to continue delivering on our promises to Cincinnati families.' Tours & Move-In Information Vista is now scheduling tours and accepting deposits for immediate move-ins. Floor plans, pricing, and tour times are available at or by calling 513-586-2229. About The Wellington at North Bend Crossing Located at 5156 North Bend Crossing in Cincinnati, Ohio, The Wellington and North Bend Crossing is a senior living campus that offers the full range of lifestyle options for older adults, from independent living to assisted living, memory care, and respite care. The campus is comprised of two Ohio-licensed residential care facilities, the Wellington at North Bend Crossing - Hilltop and the Wellington at North Bend Crossing - Vista. The community fosters independence, dignity, and engagement in a welcoming environment. About Sonida Senior Living Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 96 senior housing communities in 20 states with an aggregate capacity of nearly 10,150 residents, including 83 communities which the Company owns (four through joint ventures in a consolidated entity and four through a joint venture investment in an unconsolidated entity), and 13 communities that the Company manages on behalf of a third-party. For more information, visit
Business Wire
21 minutes ago
- Business Wire
Fujifilm Launches FDR Go iQ Portable Digital Radiography System
LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, today announced the U.S. launch of the FDR Go iQ, an innovative portable digital radiography (DR) solution built for hospitals and ambulatory surgery centers. Equipped with intuitive touchscreen controls and a display at the tube head, as well as convenient built-in smart charging, technologists can acquire x-ray room image quality at the patient bedside. 'This new portable digital radiography system represents a major step forward in imaging mobility, performance, and user experience,' said Rob Fabrizio, director of strategic marketing, medical imaging systems, FUJIFILM Healthcare Americas Corporation. 'The FDR Go iQ has an extremely slim and lightweight design, a retractable column, and an ultra-low profile, all of which enhances safety and maneuverability in even the busiest clinical settings. Additionally, the innovative built-in charging and touchscreen tube head controls ensure speed and precision wherever care is delivered.' FDR Go iQ features include: a built-in 3D camera with advanced positioning guidance and ability to upgrade to future AI technologies intelligent smart charging automated in bin connection keeps the detector powered for extended use a touchscreen tube head display and controls, provide advanced positioning and tube alignment guidance, motion detection and exam parameters easily within reach an extra-large 19-inch display for confident image verification at the bedside a slim and lightweight design at just 22.5 inches wide and 970 pounds for optimized mobility in tight spaces mark-free polyurethane wheels and 360-degree swivel casters for smooth travel and turning dedicated storage with a detector lock convenient detector holding slots at the top of the main body to hold the DR detector securely during bagging and wipe down wipes and gloves storage to support fast access and infection controls The system features innovative technologies to optimize image quality, workflow and patient safety. The FDR Go IQ coupled with FDR D-EVO III ultra-lightweight glass-free detectors feature Fujifilm's exclusive Hydro AG antibacterial coating and patented Irradiated Side Sampling (ISS) for higher-resolution and improved dose efficiency compared to conventional circuitry designs. By acquiring its data on the patient side of the circuitry, ISS increases sharpness and Detective Quantum Efficiency (DQE) and reduces scatter and blur at ultra-low doses. Additionally, the system's onboard technologist console features Fujifilm's proprietary Dynamic Visualization™ II intelligent feature recognition processing which automatically adapts to anatomic characteristics and hardware to produce exceptional images with higher detail and contrast levels throughout. The FDR Go iQ will be available for demonstration at The Association for Medical Imaging Management (AHRA) 2025 Annual Meeting and Exhibition on August 3-5 in Las Vegas. Visit the Fujifilm booth #303 and learn more online here. About Fujifilm FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis, and treatment of diseases. Fujifilm's innovative portfolio includes solutions spanning diagnostic imaging, enterprise imaging, endoscopic imaging, surgical imaging, and in-vitro diagnostics. The Non-Destructive Testing group delivers radiography solutions to ensure high accuracy inspection of transportation infrastructure, and assets within aerospace, and oil and gas industries. The company is headquartered in Lexington, Massachusetts. For more information on healthcare offerings, please visit and for NDT portfolio, please visit FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit:
